females to follow finalist
RISING STAR IN industry
Miriam Bujny
Chief Development Officer
Sapreme
Technologies
About Miriam Bujny
Miriam is the CDO at Sapreme, where she applies her scientific and drug development expertise to empower breakthrough therapeutic delivery solutions. At Sapreme, an early-stage company pushing the boundaries of next-gen treatments, Miriam leads the development of innovative therapeutics, including a program in neuromuscular diseases.
With 15+ years in translational science, Miriam has held leadership roles at ProQR, J&J, and Crucell, bridging scientific advancements and impactful patient outcomes. She thrives on building shared missions and fostering collaborative environments that drive progress while embracing the opportunities of the evolving healthcare landscape. Miriam holds a Ph.D. in Biochemistry from the University of Bristol and completed postdoctoral research at Harvard University. Above all, she believes that meaningful science and collaboration can shape the future of healthcare—impacting patients, advancing the field, and creating space for others to thrive.
Sapreme
Technologies
Sapreme is a privately funded, preclinical-stage biotech company focused on developing next-generation RNA therapeutics for genetically driven diseases. Our proprietary endosomal escape technology enables the targeted delivery of large molecules (such as ASOs and siRNAs) to intracellular targets in key tissues, including the liver, muscle, heart, and brain. With successful proof of concept in rodents and non-human primates, we are advancing our platform toward transformative therapeutic applications. Focused on neuromuscular and cardiometabolic diseases, Sapreme is building a pipeline to address high unmet medical needs. Our lead program targets Duchenne muscular dystrophy (DMD), a pediatric genetic disease with no effective treatment. We are committed to advancing our therapies to the clinic and improving outcomes for patients who currently lack viable options. Sapreme’s innovation has attracted strong investor support from firms with a proven track record in advancing high-potential biotech, underscoring confidence in our approach and the transformative potential of our RNA-based therapies. We continue to explore (co-) development partnerships and investment opportunities to accelerate our pipeline and expand our impact.
Sapreme is a privately funded, preclinical-stage biotech company focused on developing next-generation RNA therapeutics for genetically driven diseases. Our proprietary endosomal escape technology enables the targeted delivery of large molecules (such as ASOs and siRNAs) to intracellular targets in key tissues, including the liver, muscle, heart, and brain. With successful proof of concept in rodents and non-human primates, we are advancing our platform toward transformative therapeutic applications. Focused on neuromuscular and cardiometabolic diseases, Sapreme is building a pipeline to address high unmet medical needs. Our lead program targets Duchenne muscular dystrophy (DMD), a pediatric genetic disease with no effective treatment. We are committed to advancing our therapies to the clinic and improving outcomes for patients who currently lack viable options. Sapreme’s innovation has attracted strong investor support from firms with a proven track record in advancing high-potential biotech, underscoring confidence in our approach and the transformative potential of our RNA-based therapies. We continue to explore (co-) development partnerships and investment opportunities to accelerate our pipeline and expand our impact.
| Powered by: Hyphen Projects BV | Connect with us | Join TOPX | |||
| Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 | | |
© Copyright 2020 by Hyphen Projects